Roche signs global licensing pact for Simcere's experimental blood cancer drug
来源：Reuters发布于 2026-09-01
Switzerland's Roche will pay $75 million upfront to Simcere Pharmaceutical Group for rights to an experimental blood cancer drug, the Chinese drugmaker said Tuesday.
本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。